Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- AZ's New Antiplatelet Agent Ticagrelor Approved by the FDA
August 15, 2011
- Shionogi Completes New Core Research Facility in Toyonaka
August 15, 2011
- Top-100 Product Ranking Affected by Premium, Price Revisions
August 15, 2011
- RoACTEMRA Approved for sJIA in Children 2 Years or Older in Europe
August 15, 2011
- Tella Announces Research Results for Dendritic Cell Vaccine Therapy
August 15, 2011
- Aricept Has Overwhelming Advantage in AD Market in Japan: Mr Honda
August 15, 2011
- Roche's Tarceva Receives Positive Opinion from CHMP for 1st-Line NSCLC Therapy
August 15, 2011
- Korosho Starts Inviting Requests for Approval of Unapproved Drugs/Indications
August 15, 2011
- Yakult Gains Option Rights to Anticancer Drug from Proacta
August 15, 2011
- EC Approves Acquisition of Nycomed by Takeda
August 15, 2011
- First Aid for Choking
August 15, 2011
- Bayer Obtains Exclusive License for Novel Antibiotic
August 15, 2011
- Korosho Taking Public Comments on Proposed GL for Development of Prototype Pandemic Flu Vaccines
August 15, 2011
- RaQualia of Japan Aims to Become Global Drug Discovery Innovator
August 15, 2011
- Santen Creates Subsidiary in India
August 15, 2011
- Korosho Announces Revised Precautions for Diabetes Treatment Metgluco
August 15, 2011
- TOPICS 2 articles
August 15, 2011
- System to Ensure Early Price Settlement Necessary: Non-Partisan Council of Diet Members
August 15, 2011
- Dissolution Test Methods Annexed to ICH Q4B GLs Go into Effect
August 15, 2011
- Taisho Completes Acquisition of Malaysian Company
August 15, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…